These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 3104262)
1. Pharmaceutical aspects. Nasal and depot formulations of leuprolide. Shimamoto T J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262 [No Abstract] [Full Text] [Related]
2. Clinical development of nafarelin acetate. Phase I and phase II studies. Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357 [No Abstract] [Full Text] [Related]
3. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment. Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851 [No Abstract] [Full Text] [Related]
4. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. Okada H; Heya T; Ogawa Y; Shimamoto T J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294 [TBL] [Abstract][Full Text] [Related]
5. Leuprolide acetate for the treatment of endometriosis. Miller JD Prog Clin Biol Res; 1990; 323():337-41. PubMed ID: 2106145 [No Abstract] [Full Text] [Related]
6. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate. Okada H; Heya T; Ogawa Y; Toguchi H; Shimamoto T Pharm Res; 1991 May; 8(5):584-7. PubMed ID: 1907735 [TBL] [Abstract][Full Text] [Related]
7. [Hormone kinetics in suppression with monthly Enantone depot preparations]. Schilling A Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075 [No Abstract] [Full Text] [Related]
8. The treatment of prostatic cancer by LH-RH agonist. Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552 [No Abstract] [Full Text] [Related]
9. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer]. Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071 [No Abstract] [Full Text] [Related]
10. Monthly dosage form of leuprolide approved by FDA. Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158 [No Abstract] [Full Text] [Related]
11. Leuprolide for prostate cancer. Med Lett Drugs Ther; 1985 Aug; 27(694):71-2. PubMed ID: 2410765 [No Abstract] [Full Text] [Related]
12. Randomised, double-blind study of estramustine phosphate and leuprolide acetate. De la Grange AB Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555 [No Abstract] [Full Text] [Related]
13. Leuprolide: a review of its effects in animals and man. Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664 [No Abstract] [Full Text] [Related]
14. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog]. Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936 [TBL] [Abstract][Full Text] [Related]
15. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. Ogawa Y; Okada H; Heya T; Shimamoto T J Pharm Pharmacol; 1989 Jul; 41(7):439-44. PubMed ID: 2570847 [TBL] [Abstract][Full Text] [Related]
16. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally. Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230 [TBL] [Abstract][Full Text] [Related]
17. Leuprolide: a review of its effects in animals and man. Drago JR; Rohner T; Santen R; Manni A; English H; Lipton A; Harvey H Br J Clin Pract; 1985 Feb; 39(2):77-9. PubMed ID: 3921048 [No Abstract] [Full Text] [Related]
18. Intranasal administration of melatonin starch microspheres. Mao S; Chen J; Wei Z; Liu H; Bi D Int J Pharm; 2004 Mar; 272(1-2):37-43. PubMed ID: 15019067 [TBL] [Abstract][Full Text] [Related]
19. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. Schlegel P BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147 [No Abstract] [Full Text] [Related]
20. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Kostanski JW; Dani BA; Schrier B; DeLuca PP Pharm Res; 2000 Apr; 17(4):445-50. PubMed ID: 10870989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]